CDKN2A and melanoma: The authors concluded that complete p16 loss is a strong indicator of melanoma and that the presence of a heterogeneous expression pattern warrants careful pathological assessment, reinforcing the value of p16 IHC as an ancillary tool in challenging melanocytic lesions.